drugset
drugset / Trial / NCT00110032

Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors

NCT00110032 ↗

Phase 1 Terminated 46 enrolled National Cancer Institute (NCI)
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This phase I trial is studying the side effects of fluorine F18 EF5 when given during positron emission tomography to find oxygen in tumor cells of patients who are undergoing surgery or biopsy for newly diagnosed brain tumors. Diagnostic procedures using fluorine F 18 EF5 and positron emission tomography to detect tumor hypoxia may help in planning cancer treatment

Timeline

Start
2005-06
Primary completion
2007-01
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject EF5 Diagnostic / imaging agent — Intravenous

Indications

adult anaplastic ependymoma adult brain ependymoma adult brainstem glioma adult central nervous system germ cell tumor adult choroid plexus neoplasm adult glioblastoma adult medulloblastoma adult oligodendroglioma adult pineoblastoma anaplastic astrocytoma anaplastic oligodendroglioma benign meningioma craniopharyngioma diffuse astrocytoma ependymoblastoma giant cell glioblastoma gliosarcoma grade II meningioma grade III meningioma meningeal melanocytoma meninges hemangiopericytoma myxopapillary ependymoma pilocytic astrocytoma pineocytoma subependymoma supratentorial primitive neuroectodermal tumor